Cargando…

EGFR Status Assessment for Better Care of Early Stage Non-Small Cell Lung Carcinoma: What Is Changing in the Daily Practice of Pathologists?

The recent emergence of novel neoadjuvant and/or adjuvant therapies for early stage (I-IIIA) non-small cell lung carcinoma (NSCLC), mainly tyrosine kinase inhibitors (TKIs) targeting EGFR mutations and immunotherapy or chemo-immunotherapy, has suddenly required the evaluation of biomarkers predictiv...

Descripción completa

Detalles Bibliográficos
Autor principal:	Hofman, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392580/ https://www.ncbi.nlm.nih.gov/pubmed/34440926 http://dx.doi.org/10.3390/cells10082157

Ejemplares similares

Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner
por: Bontoux, Christophe, et al.
Publicado: (2022)

Early stage lung cancer: pathologist’s perspective
por: Boggio, Francesca, et al.
Publicado: (2020)

Challenges of the eighth edition of the American Joint Committee on Cancer staging system for pathologists focusing on early stage lung adenocarcinoma
por: Wang, Yu‐Ting, et al.
Publicado: (2023)

What are Indian oral pathologists talking about?
por: Ranganathan, K
Publicado: (2017)

Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?
por: Tanzawa, Shigeru, et al.
Publicado: (2019)

Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist’s Perspective
por: Brega, Elisa, et al.
Publicado: (2014)

NTRK insights: best practices for pathologists
por: Hechtman, Jaclyn F.
Publicado: (2021)

Impact of COVID-19 on the practice of breast pathologists: a survey of breast pathologists in the UK and Ireland
por: Elghobashy, Mirna, et al.
Publicado: (2023)

EGFR‐mutated stage IV non‐small cell lung cancer: What is the role of radiotherapy combined with TKI?
por: Liu, Bailong, et al.
Publicado: (2021)

EGFR-Mutant Non-Small-Cell Lung Cancer at Surgical Stages: What Is the Place for Tyrosine Kinase Inhibitors?
por: Cansouline, Xavier, et al.
Publicado: (2022)

Diminutive and Small Colorectal Polyps: The Pathologist's Perspective
por: Kang, Yun Kyung
Publicado: (2014)

Ductal Carcinoma In Situ: What the Pathologist Needs to Know and Why
por: Bane, Anita
Publicado: (2013)

What are the priorities of pathologists’ activities during COVID-19 emergency?
por: Barbareschi, Mattia, et al.
Publicado: (2020)

PD−L1 immunostaining: what pathologists need to know
por: Akhtar, Mohammed, et al.
Publicado: (2021)

Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?
por: Lemmon, Christopher, et al.
Publicado: (2020)

ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice
por: Hofman, Paul
Publicado: (2017)

Problems for Pathologists
Publicado: (1876)

The Pathologist as Poet
por: Domen, Ronald E.
Publicado: (2016)

To be or not to be an oral pathologist
por: Ramesh, V
Publicado: (2019)

Pathologists’ Fees
Publicado: (1885)

Staging Work-up for Early Lung Cancer: The More the Better?
por: Choi, Chang Min, et al.
Publicado: (2017)

A practical guide to placental examination for forensic pathologists
por: Mittal, Namita, et al.
Publicado: (2019)

HIMSS10 – Perspectives from a newcomer pathologist and a seasoned attendee pathologist: Pathologists should attend!
por: Carter, Alexis B., et al.
Publicado: (2010)

Running GAGs: myxoid matrix in tumor pathology revisited: What’s in it for the pathologist?
por: Willems, Stefan M., et al.
Publicado: (2009)

What is the best way to measure renal fibrosis?: A pathologist's perspective
por: Farris, Alton B, et al.
Publicado: (2014)

Correction: PD − L1 immunostaining: what pathologists need to know
por: Akhtar, Mohammed, et al.
Publicado: (2022)

EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice
por: Gahr, S, et al.
Publicado: (2013)

Unclassifiable interstitial lung disease: a pathologist's perspective
por: Jones, Kirk D.
Publicado: (2018)

Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer
por: Ling, Yun, et al.
Publicado: (2016)

EGFR and non-small cell lung cancer: implications for surgical practice
por: Varela, Gonzalo, et al.
Publicado: (2020)

Review by urological pathologists improves the accuracy of Gleason grading by general pathologists
por: Nakai, Yasushi, et al.
Publicado: (2015)

Intronic variant of EGFR is associated with GBAS expression and survival outcome of early‐stage non‐small cell lung cancer
por: Hong, Mi Jeong, et al.
Publicado: (2018)

Incomplete surgical staging in clinical early-stage ovarian cancer: guidelines versus daily practice
por: Laven, P, et al.
Publicado: (2021)

Correction to: A practical guide to placental examination for forensic pathologists
por: Mittal, Namita, et al.
Publicado: (2021)

Videofluoroscopy Practice in India: A Survey of Speech-Language Pathologists
por: Krishnamurthy, Rahul, et al.
Publicado: (2022)

The power of immunotherapy plus platinum–based chemotherapy for locally advanced or early stage non-small cell lung cancer
por: Hofman, Paul
Publicado: (2020)

Tissue management in precision medicine: What the pathologist needs to know in the molecular era
por: Souza da Silva, Ricella, et al.
Publicado: (2022)

Association of Clinical Pathologists
Publicado: (2002)

The Relationship of the Pathologist to the Surgeon
Publicado: (1905)

Pathologist to the Edinburgh Infirmary
Publicado: (1902)

Cannot write session to /tmp/vufind_sessions/sess_hee6gts5f2do5a8mojf7vrvd20